19.01.2015, 16:24
Beximco Pharma commences export to Australia
OREANDA-NEWS. Beximco Pharmaceuticals Limited ("BPL" or "Company"; AIM Symbol: BXP), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces the commencement of export to Australia, with the launch of Pantoprazole, a drug for treating gastrointestinal disorder. This is the first time a pharmaceutical product from Bangladesh has been exported to Australia.
To mark the delivery of the first consignment, and to celebrate this milestone achievement for Beximco Pharma, a brief ceremony was held at the Company's factory premises in the presence of the Australian High Commissioner to Bangladesh, His Excellency Greg Wilcock. The High Commissioner was accompanied by Minhaz Chowdhury, Bangladesh Country Manager, Australian Trade Commission. Beximco Pharma's Chief Operating Officer, Rabbur Reza, received this delegation at the factory premises located in Tongi. Senior officials from Beximco Pharma, as well as representatives from Singapore Airlines and Capital Logistics, were also present at the ceremony.
The High Commissioner said; "We hope that with the commencement of this pharmaceutical export, business and cooperation between Australia and Bangladesh will continue to expand and reach new heights."
Beximco Pharma currently has the highest number of global accreditations in the Bangladesh pharma sector and is a leading exporter of medicines in the country. The Company's state-of-the-art manufacturing facilities have been certified by global regulatory authorities such as TGA Australia, AGES Austria (for European Union), Health Canada, ANVISA Brazil, INVIMA Colombia and TFDA (Taiwan), among others.
About Beximco Pharmaceuticals Limited
Founded in 1976 and based in Dhaka, Bangladesh, Beximco Pharma manufactures and sells generic pharmaceutical formulation products and active pharmaceutical ingredients. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies. The Company operates from a 23 acre site in Dhaka and has manufacturing facilities for producing various drugs in different delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, prefilled syringes, injectables, nebulizer solutions, oral soluble films etc. Ensuring access to quality medicines is the powerful aspiration that motivates 3,000 employees of the Company.
Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of Australia, European Union, and Brazil, among others. The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in Africa, including Mauritius, Kenya, Ghana and Nigeria, Pacific Island, Latin and Central American countries, Middle East, Central Asia, South East Asia, including Singapore, Malaysia, Philippines and Hong Kong, and Europe, Austria and Australia.
To mark the delivery of the first consignment, and to celebrate this milestone achievement for Beximco Pharma, a brief ceremony was held at the Company's factory premises in the presence of the Australian High Commissioner to Bangladesh, His Excellency Greg Wilcock. The High Commissioner was accompanied by Minhaz Chowdhury, Bangladesh Country Manager, Australian Trade Commission. Beximco Pharma's Chief Operating Officer, Rabbur Reza, received this delegation at the factory premises located in Tongi. Senior officials from Beximco Pharma, as well as representatives from Singapore Airlines and Capital Logistics, were also present at the ceremony.
The High Commissioner said; "We hope that with the commencement of this pharmaceutical export, business and cooperation between Australia and Bangladesh will continue to expand and reach new heights."
Beximco Pharma currently has the highest number of global accreditations in the Bangladesh pharma sector and is a leading exporter of medicines in the country. The Company's state-of-the-art manufacturing facilities have been certified by global regulatory authorities such as TGA Australia, AGES Austria (for European Union), Health Canada, ANVISA Brazil, INVIMA Colombia and TFDA (Taiwan), among others.
About Beximco Pharmaceuticals Limited
Founded in 1976 and based in Dhaka, Bangladesh, Beximco Pharma manufactures and sells generic pharmaceutical formulation products and active pharmaceutical ingredients. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies. The Company operates from a 23 acre site in Dhaka and has manufacturing facilities for producing various drugs in different delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, prefilled syringes, injectables, nebulizer solutions, oral soluble films etc. Ensuring access to quality medicines is the powerful aspiration that motivates 3,000 employees of the Company.
Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of Australia, European Union, and Brazil, among others. The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in Africa, including Mauritius, Kenya, Ghana and Nigeria, Pacific Island, Latin and Central American countries, Middle East, Central Asia, South East Asia, including Singapore, Malaysia, Philippines and Hong Kong, and Europe, Austria and Australia.
Комментарии